DLBCL ad alto rischio, dallo studio frontMIND nuove prospettive prima linea
The addition of the anti-CD19 monoclonal antibody tafasitamab to lenalidomide and R-CHOP has resulted in significant benefits in terms of treatment efficacy and reduced risk of disease progression. Commentary by Gianluca Gaidano (Director of the Hematology Unit - AOU Maggiore della Carità, Novara) and Umberto Vitolo (Hematology - IRCCS Oncology Institute of Candiolo).
▶︎
Liso-cel in the treatment of large B-cell lymphomas: the state of the art
▶︎
LMA FLT3-ITD mutata, nuove evidenze per quizartinib vs midostaurina
▶︎
Use These 5 Food Hacks To Heal The Body & STARVE CANCER I Dr. William Li
▶︎
Epatite C, nuove terapie e comportamenti a rischio
▶︎
New developments and updates in multiple myeloma treatment: An overview
▶︎
What do tech pioneers think about the AI revolution? - The Engineers, BBC World Service
▶︎
I tumori cistici del pancreas: tanto rumore per nulla
▶︎
The Cardiologist Warns of the Morning Mistake That Causes Heart Attacks After 60
▶︎
Ivermectin to Treat Cancer? Get the FACTS
▶︎
Confirmations and new evidence for pirtobrutinib in chronic lymphocytic leukemia
▶︎
Different therapeutic approaches to Multiple Myeloma
▶︎
It's NOT Memory - 5 Early Dementia Signs Everyone Misses
▶︎
Novità e conferme nel trattamento del mieloma multiplo, un'overview
▶︎
This Common Food Is Feeding Your Cancer Cells - Dr. William Li
▶︎
Diabete, nuovi farmaci e nuovi dispositivi per il controllo e la terapia
▶︎
How does chemotherapy work? A brief comparison to immunotherapy.
▶︎
Mieloma multiplo: oggi la guarigione funzionale è un obiettivo più vicino | Dott. Giuseppe Mele
▶︎
La sepsi
▶︎
Politics Chat, June 25, 2026
▶︎